Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METRE-PL: Metreleptin in Partial Lipodystrophy
NCT05164341Phase 3Active, not recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2021
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
A Phase 3 trial of metreleptin in familial partial lipodystrophy (FPLD), sponsored by Chiesi Farmaceutici S.p.A.. Started Dec 2021; status: active, not recruiting.
02
Drugs
metreleptin
03
Conditions
familial partial lipodystrophy (FPLD)
Beyond the preview
Go deeper on NCT05164341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164341.